Trevor Allred
Stock Analyst at Oppenheimer
(4.68)
# 123
Out of 5,182 analysts
19
Total ratings
77.78%
Success rate
32.74%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Trevor Allred
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TBPH Theravance Biopharma | Downgrades: Perform | n/a | $16.02 | - | 2 | Mar 5, 2026 | |
| LGND Ligand Pharmaceuticals | Maintains: Outperform | $275 → $277 | $199.59 | +38.78% | 9 | Feb 27, 2026 | |
| BBIO BridgeBio Pharma | Maintains: Outperform | $83 → $81 | $73.15 | +10.73% | 2 | Feb 25, 2026 | |
| LEGN Legend Biotech | Initiates: Outperform | $75 | $19.14 | +291.85% | 1 | Jan 7, 2026 | |
| DSGN Design Therapeutics | Initiates: Outperform | $18 | $11.23 | +60.28% | 1 | Jan 7, 2026 | |
| MBX MBX Biosciences | Maintains: Outperform | $38 → $80 | $32.99 | +142.50% | 2 | Sep 23, 2025 | |
| PVLA Palvella Therapeutics | Initiates: Outperform | $85 | $123.46 | -31.15% | 1 | Sep 9, 2025 | |
| INVA Innoviva | Initiates: Outperform | $35 | $22.99 | +52.24% | 1 | Aug 11, 2025 |
Theravance Biopharma
Mar 5, 2026
Downgrades: Perform
Price Target: n/a
Current: $16.02
Upside: -
Ligand Pharmaceuticals
Feb 27, 2026
Maintains: Outperform
Price Target: $275 → $277
Current: $199.59
Upside: +38.78%
BridgeBio Pharma
Feb 25, 2026
Maintains: Outperform
Price Target: $83 → $81
Current: $73.15
Upside: +10.73%
Legend Biotech
Jan 7, 2026
Initiates: Outperform
Price Target: $75
Current: $19.14
Upside: +291.85%
Design Therapeutics
Jan 7, 2026
Initiates: Outperform
Price Target: $18
Current: $11.23
Upside: +60.28%
MBX Biosciences
Sep 23, 2025
Maintains: Outperform
Price Target: $38 → $80
Current: $32.99
Upside: +142.50%
Palvella Therapeutics
Sep 9, 2025
Initiates: Outperform
Price Target: $85
Current: $123.46
Upside: -31.15%
Innoviva
Aug 11, 2025
Initiates: Outperform
Price Target: $35
Current: $22.99
Upside: +52.24%